🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

518 results for “Cho” Clear

  1. KarXT, KarXT, KarXT, KarXT, KarXT, Placebo

    Bristol-Myers Squibb Australia Pty Ltd

    Psychosis Associated with Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  2. Ketanest-S 25 Multi-dose, oplossing voor injectie 25 mg/ml

    Disc Medicine

    Non-psychotic therapy resistant unipolar depression

    phase 3 small molecule active

    1 trial

  3. LEUPRORELIN ACETATE, BAY 1841788, NUBEQA 300 mg film-coated tablets, TRIPTORELIN, DEGARELIX, GOSERELIN

    Ningbo Cancer Hospital

    Castrate-resistant prostate cancer with oligometastases on functional imaging (PSMA or choline/fluciclovine-positron-emission tomography).

    phase 3 small molecule active

    1 trial

  4. LMT (atorvastatin, simvastatin, or rosuvastatin)

    Regeneron UK Limited

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  5. Lapaquistat acetate

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    4 trials

  6. Lapaquistat acetate and atorvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  7. Lapaquistat acetate and current lipid-lowering treatment

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    1 trial

  8. Lapaquistat acetate and rosuvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  9. Lapaquistat acetate and simvastatin

    Takeda

    Hypercholesterolemia

    phase 3 small molecule completed

    2 trials

  10. Lapaquistat acetate and stable statin therapy

    Takeda

    Hypercholesterolemia

    phase 3 small molecule terminated

    2 trials

  11. Lucentis 10 mg/ml solution for injection, FARICIMAB

    Hoffmann-La Roche

    Choroidal neovascularization secondary to pathologic myopia

    phase 3 small molecule active

    1 trial

  12. MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  13. MK-0616, Placebo to MK-0616

    Merck Sharp and Dohme

    ​Heterozygous Familial Hypercholesterolemia​ in pediatric patients

    phase 3 small molecule active

    1 trial

  14. MK-2870, PACLITAXEL ALBUMIN-BOUND, -, PACLITAXEL , -, -, DOXORUBICIN , PARACETAMOL, COMBINATIONS EXCL. PSYCHOLEPTICS

    Merck Sharp and Dohme

    Endometrial cancer

    phase 3 small molecule active

    1 trial

  15. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Progressive Familial Intrahepatic Cholestasis (PFIC)

    phase 3 small molecule completed

    3 trials

  16. Maralixibat

    Mirum Pharmaceuticals International B.V.

    Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)

    phase 3 small molecule active

    1 trial

  17. Microcrystalline cellulose, Sodium Chloride, Magnesium Stearate, MK-0616

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  18. Mipomersen

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  19. Mipomersen sodium

    IONIS PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  20. NUC01, Placebo to NUC01

    Dr. Falk Pharma GmbH

    primary sclerosing cholangitis (PSC)

    phase 3 small molecule active

    1 trial

  21. NUT01

    Dr. Falk Pharma GmbH

    Primary Sclerosing Cholangitis (PSC)

    phase 3 small molecule active

    1 trial

  22. Nomlabofusp, Placebo to Nomlabofusp

    Larimar Therapeutics

    Friedreich’s ataxia is the most common inherited ataxia in humans and results from a deficiency of the mitochondrial protein, FXN. Friedreich’s ataxia is a rare, progressive, multisystem disease with an incidence that is estimated to be 1:29,000, and a carrier frequency of ~1:85.

    phase 3 small molecule active

    1 trial

  23. OCA 5MG IR +BZF 400 MG SR

    Lacuna Pharma Pty Ltd

    Primary Biliary Cholangitis (PBC)

    phase 3 small molecule active

    1 trial

  24. PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Major Depressive Disorder

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources